a public good project by the
Synthesis
Company
of California

© 2026

Pamela Shaw | doi.page

0 works0 citations0 h-index

Pamela Shaw

Diamond Materials (United States)(US)Mersana Therapeutics (United States)(US)

Publications by Year

Research Areas

interferon and immune responses, Neuroblastoma Research and Treatments, Ubiquitin and proteasome pathways, Radiopharmaceutical Chemistry and Applications, HER2/EGFR in Cancer Research

Most-Cited Works

→ Studying clonal dynamics in response to cancer therapy using high-complexity barcoding(2015)521 cited
→ Effect of MWCNT size, carboxylation, and purification on in vitro and in vivo toxicity, inflammation and lung pathology(2013)156 cited
→ Autophagy deficiency in macrophages enhances NLRP3 inflammasome activity and chronic lung disease following silica exposure(2016)103 cited
→ Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses(2024)59 cited
→ Substitution of atenolol for propranolol in a case of propranolol- related depression(1982)53 cited
→ Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer(2023)35 cited

→ Natural Foxp3+ regulatory T cells inhibit Th2 polarization but are biased toward suppression of Th17-driven lung inflammation(2010)

29 cited

→ Multiwalled Carbon Nanotubes of Varying Size Lead to DNA Methylation Changes That Correspond to Lung Inflammation and Injury in a Mouse Model(2019)29 cited

→ XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells(2025)25 cited

→ Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines(2020)25 cited